TRCT
NUTX

Tower Research Capital (TRC)’s Nutex Health NUTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio NUTX Stock Details NUTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.4K Buy
383
+143
+60% +$17.5K ﹤0.01% 3018
2025
Q4 		$39.5K Sell
240
-490
-67% -$65K ﹤0.01% 2607
2025
Q3 		$75.4K Buy
730
+578
+380% +$56.7K ﹤0.01% 2223
2025
Q2 		$18.9K Sell
152
-51
-25% -$6.59K ﹤0.01% 3715
2025
Q1 		$9.55K Buy
+203
New +$9.9K ﹤0.01% 3761
2024
Q4 		– Sell
-281
Closed -$6.1K – 5905
2024
Q3 		$6.1K Sell
281
-1,015
-78% -$14.6K ﹤0.01% 4184
2024
Q2 		$7.71K Buy
1,296
+770
+146% +$5.55K ﹤0.01% 4432
2024
Q1 		$7.57K Buy
526
+145
+38% +$2.92K ﹤0.01% 4179
2023
Q4 		$10.3K Buy
+381
New +$11.9K ﹤0.01% 4267
2023
Q3 		– Sell
-238
Closed -$15K – 6146
2023
Q2 		$15K Buy
238
+60
+34% +$5.15K ﹤0.01% 3651
2023
Q1 		$27K Buy
178
+152
+585% +$30.8K ﹤0.01% 3116
2022
Q4 		$7K Sell
26
-15
-37% -$2.88K ﹤0.01% 4593
2022
Q3 		$9K Sell
41
-10
-20% -$4.24K ﹤0.01% 4673
2022
Q2 		$25K Buy
+51
New +$60.1K ﹤0.01% 3567

Other funds holding NUTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.37B AUM 36.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WC
Winmill & Co Rochester, New York $347M AUM 37.48% 1-Year Est. Return

Tower Research Capital (TRC)'s NUTX Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Nutex Health (NUTX) stake by 60% in Q1 2026, buying an estimated $17.5K and bringing the position to 383 shares worth $36.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3018.

Tower Research Capital (TRC) first reported a position in NUTX in Q2 2022 and has held it in 14 quarters since. The position peaked at $75.4K in Q3 2025. 129 funds tracked by Wall St. Rank hold NUTX as of Q1 2026.

  • Tower Research Capital (TRC) held 383 shares of Nutex Health worth $36.4K as of Q1 2026.
  • Tower Research Capital (TRC) bought 143 Nutex Health shares in Q1 2026, an estimated $17.5K.
  • Nutex Health made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3018 holding.
  • Tower Research Capital (TRC) first reported a position in Nutex Health in Q2 2022 and has held it in 14 quarters since.
  • Tower Research Capital (TRC)'s Nutex Health position peaked at $75.4K in Q3 2025.
  • 129 funds tracked by Wall St. Rank held Nutex Health as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.